Lupin Limited
| Company type | Public |
|---|---|
| BSE: 500257 NSE: LUPIN | |
| Industry | Pharmaceuticals |
| Founded | 1968 |
| Founder | Desh Bandhu Gupta |
| Headquarters | , India |
Key people | Vinita D. Gupta (CEO) Nilesh Gupta (MD) |
| Products | |
| Revenue | ₹22,192 crore (US$2.6 billion) (2025) |
| ₹5,277 crore (US$620 million) (2025) | |
| ₹3,281 crore (US$390 million) (2025) | |
| Total assets | ₹29,204 crore (US$3.5 billion) (2025) |
| Total equity | ₹17,294 crore (US$2.0 billion) (2025) |
Number of employees | 20,000+ (2023) |
| Website | www |
| Footnotes / references Financials as of 31 March 2025. | |
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.The company operates in multiple international markets including the United States, Japan, Europe, and Australia..